BRPI0706675A2 - improved morinda citrifolia products for animal administration - Google Patents

Abstract

IMPROVED PRODUCTS OF MORINDA CITRIFOLIA FOR ADMINISTRATION TO ANIMALS. Food products for animals reinforced with Morinda citrifolia are provided in both liquid and dry form. Both contain pasteurized fruit puree and other M.citrifolia plant products.

Description

IMPROVED MORINDA CITRIFOLIA PRODUCTS FOR ANIMAL ADMINISTRATION

1. Field of the invention

The field of the invention relates to products that can be administered to various animals, and more particularly Morinda citrifolia-reinforced products.

2. Background

Animal feed products designed for domestic animals, farm animals or pet animals are generally and preferably prepared as total feed, which means that the specific feed contains all the necessary nutrients and supplements necessary to maintain the health and vigor of the pet. The food composition is balanced in nutrition so that a diet limited to that specific ration will meet all the nutritional needs of the animal. Typical ingredients contained in a pet food formulation are protein, carbohydrates, fat, vitamins and minerals. Each of these is present in varying percentages by weight of the composition or specific formulation sufficient to meet the complete nutritional requirements of the animal. In addition, other ingredients may be added depending on the specific needs of the animal for which the food is intended.

A wide variety of different pet food formulations are commercially available. In the past, the nutrients or ingredients in these formulations were not typically designed to provide an animal with specific advantages if desired or necessary. Recently, however, animal feed formulations have been designed with a specific purpose. Many pet food formulations available on the market today are specialized supplies for animals of different ages, different breeds, or those with certain needs such as obesity, bone loss, weight gain, disease or illness. Other formulations address different energy requirements among animals. An additional segment of the pet food market incorporates differences in use of ingredients or product form, which tend to lend themselves to more attractive flavors or avariety.

For example, the feed may be specifically designed as a selective COX-2 inhibitor. Eicosanoids are continuously synthesized in membranes from 20-carbon fatty acid chains that contain at least three double bonds. There are four major classes of eicosanoids - prostaglandins, prostacyclins, thromboxanes and leukotrienes, all of which are mainly made up of arachidonic acid. The synthesis of all but leukotrienes involves the enzyme cyclooxygenase (COX), which has two distinct isozymes: constitutive COX-I and inducible COX-2. These pathways are targets for a large number of drug therapies because eicosanoids play an important role in pain, fever and inflammation. For example, non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, Celebrex® and Vioxx® reduce inflammation through COX inhibition, resulting in blockage of the first oxidation step. In addition, COX inhibition is linked to several other benefits, such as avoiding cancer treatment, avoiding preterm birth and / or treating Alzheimer's disease.

In addition to COX, inhibition of cytokines, specifically Interleukin-β (IL-β), Interleukin-6 (IL-6), and Tumor-Necrosis Factor (TNF-α) have proven to have many clinical uses. In general cytokines are intercellular regulatory proteins that mediate a multitude of immune biological functions, and in certain pathological situations, particularly autoimmune diseases, chronic inflammatory diseases, and some leukemias, cytokine production is unregulated.

In the past, Pacific Islanders' native residents have seen health and animal health benefits from eating Morinda citrifolia fruit sometimes referred to as "Noni". Although some animals, such as pigs, have been documented consuming the fruit in its natural state, most animals have difficulty consuming the naturally occurring Morinda citrifolia fruit. Due to its strong smell and taste, many animals will not consume the product and will avoid contact with the seed fruit. Since the fruit has a limited shelf life and is therefore very difficult to transport from the South Pacific, it is impractical to import and supply fruit to animals in North America. Moreover, while some large animals may benefit from the consumption of the whole fruit, poultry, small mammals and fish would find it difficult to penetrate the outer layer of the fruit and receive any substantial benefit from the small amount of fruit they could consume. that would soon become dirty with rotting fruit As a result, while some animals have been able to take advantage of the benefits of naturally occurring fruits, whole fruit has never been a viable pet food.

High morbidity among new farm animals is a problem, which can result in severe financial losses for farmers and ranchers. The present methods of controlling morbidity involve a standard grain or oat diet for farm animals and poultry, and antibiotic inoculations.

In new cattle ("calves") this problem is particularly significant. Weaning, processing and transport of fat bulls is known to be very stressful and often leads to high rates of mortality and morbidity. For example, in a six-year study more than 15% of fat bull cattle had bovine respiratory disease (BRD), and approximately 70% of feedlot death losses are attributable to BRD. However, death losses are often not the largest costs. . Weight loss, lower daily gain, carcass degradation, drug costs and carcass drug waste can total $ 50.00 - $ 100.00 per animal with no loss on death.

A drop in frequency and duration of eating and drinking are good indicators of morbidity. Feed intake of dry matter for calves during the first 28 days of feeding was 32% lower in sick calves than in their healthy counterparts; Additionally, the average daily weight gain during this period was 0.01 kg compared to the normal weight gain of 0.59 kg. Thus, nutritional interventions should take into account that calves that are sicker are those that are less likely to obtain the nutrition they require through surface feed.

Preconditioning of calves by vaccination, habituating them before weaning, and / or prophylactic administration of antibiotics often reduces morbidity and mortality during the initial 2-4 weeks after transport to a new site. The inability of the farmer to recover the costs associated with preconditioning inhibited the adoption of these practices.

Good nutrition is known to enhance emulated immunity. The common addition of immune stimulating nutrients such as zinc and vitamin E to the diet of fat bulls provides formation blocks essential to form an immune defense. Notwithstanding published research on nutritional intervention, studies were not consistently positive indicating that there was still an unidentified deficiency in the formulations studied.

As most common medical treatments for the numerous medical problems discussed above may involve serious side effects, compositions containing natural and nutraceutical products that would address these less contraindicated diseases and syndromes would decrease the development of highly desirable antibiotic resistance, not only to alleviate the suffering. in animals as well as to improve meat quality and human health.SUMMARY OF THE INVENTION

The present invention is directed to various formulas and methods of administering various Morinda citrifolia-reinforced products to animals to improve physiological condition and ameliorate and / or prevent various diseases. Therefore, preferred embodiments of the present invention provide an M. citrifolia-reinforced product which may be administered to animals. . Some modalities provide an animal product having significant health benefits.

Some embodiments of the present invention relate to various methods of using specially processed components of the Blackberry or Morinda citrifoliaL plant. to inhibit COX-2, TNF-α, IL-β, IL-8 & IL-6.

Some embodiments of the invention include one or more processed Morinda citrifolia components such as: extract from Morinda citrifolia leaves, hot leaf extract, processed Morindacitrifolia leaf ethanol extract, steam distilled extract of processed Morinda citrifolia leaf, Morinda citrifolia fruit, Morinda citrifolia extract, Morinda citrifolia fibradietetic, Morindacitrifolia puree juice, Morinda citrifolia puree, Juice concentrate Morinda citrifolia puree, Morinda citrifolia puree juice concentrate, Frozen, concentrated Morinda fruit juice and evaporated concentration of Morinda citrifolia fruit juice, whole fresh fruit of Morinda citrifolia, whole dried fruit of Morindacitrifolia, or any other processed Morinda citrifolia seed (ie toasting, blanching, microwaving, heat treatment, soaking in water or water solutions salts or chemical compounds) , whole Morindacitrifolia fruit with buds or attached flowers, leaf extracts, leaf juice, and untreated fat free seed extracts.

Preferred embodiments of the present invention provide delivery systems, methods and apparatus for providing animals with food products containing Morindacitrifolia puree and other additives such as seed extracts, fatty acids and minerals. Examples of such delivery systems include pellets, extruded pieces, extruded flakes, penetrated pieces, formaliquid distribution through a water system or salt deposit tank system, gelatinous and semi-solid forms, low moisture gels, low moisture gel pellets. , bran, paste, loose kibble, sweet kibble, and liquid purge. The present invention envisages administering these various forms of Morinda citrifolia-reinforced products by integrating the products into the feed typically provided to the animal or as a surface fertilizer. Other methods of administration include colostrum administered to calves born shortly after birth, or dipping Morinda citrifolia-reinforced products to improve mastitis.

BRIEF DESCRIPTION OF DRAWINGS

In order that the subject matter from which the above and other advantages of the invention are obtained, a more specific description of the invention described briefly above will be provided by reference to specific embodiments thereof which are illustrated in the accompanying drawings. Understanding that these drawings represent only typical features of the invention and should not therefore be construed as limiting their scope, the invention will be described and explained with further specificity and detail through the use of the accompanying drawings, in which:

Figure 1 is a representation of a net distribution device;

Figure 2 is a representation of a solid salt deposit block; e Figure 3 is a representation of a system of

supply for solid form products such as bran, pellets, flakes or pieces.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention contemplates administration of various forms of M. citrifolia with and without additional nutrients. Non-limiting examples of products that may be administered to animals include: M. citrifolia plus glycosaminoglycans, M. citrifolia plus hyaluronic acid, M. citrifolia plus glucosamine HCl, M. citrifolia plus glucosamine sulfate, and M. citrifolia plus decondroitin sulfate. Other nonlimiting examples of formulations containing M. citrifolia which may be administered to animals include: M. citrifolia plus essential amino acids, M. citrifolia plus essential fatty acids, M. citrifoliamore long chain fatty acids, M. citrifolia plus omega 3 fatty acids, M. citrifolia plus omega 6 fatty acids, M. citrifolia plus macro minerals, M.citrifolia plus micro minerals, M. citrifolia more peptide chains, M. citrifolia plus branched chain amino acids, M. citrifolia puree plus noniinteira seeds, M. citrifolia puree plus whole nonitorrada seeds, M. citrifolia puree plus fat denoni seeds, whole toast, M puree citrifoliamore non-fat roasted cracked noni seeds, mashed M. citrifolia plus roasted noni cracked seeds, M. citrifolia puree plus grounded noni seeds, M. citrifolia puree plus fat roasted nonimoida seeds, M. citrifolia puree non-roasted non-fat flaked seeds, M.citrifolia puree plus non-roasted non-flaked seeds puree M. citrifolia more non-fat seeds that of non-extruded roasted and M. citrifolia puree plus extruded noni roasted seeds and seed extracts.

1. General description of the plant Morinda citrifolia L.

The Blackberry or Morinda citrifolia plant, known scientifically as Morinda citrifolia L. (nMorinda citrifolia ") is a shrub or small tree with a comaté 10 m in height. The leaves are oppositely arranged with an elliptical oval shape. The small white flowers are contained in a cluster similar to the head, globose, fleshy.The fruits are large, fleshy and ovoid.At ripening, they are creamy white and edible, but have an unpleasant odor and taste.Plants are native to southwest Asia and spread in the early to a wide It grows wildly randomly and is grown in plantations and small individual flowerbeds.The Morinda citrifolia flowers are small, white, with three to five tubular, fragrant lobes and approximately 1.25 cm in length. The flowers develop into compound fruits, composed of many small groups, fused into an ovoid body. , ellipsoid or rounded, with clods, waxy, white, greenish or yellowish, semitranslucent. The fruit contains "eyes" on its surface, similar to a potato. Fruit is succulent, bitter, opaque yellow or yellowish white, and contains numerous lumps with 2 cells, winged, oblong-triangular, hard, brown-red, each containing four seeds. When fully ripe, the fruit has a sharp odor like rancid cheese. Although fruit is eaten by various nationalities as food, the common Morinda citrifolia plant has traditionally been a source of red and yellow dye.

2. Morinda citrifolia leaf processing

The leaves of the Morinda citrifolia plant are a possible component of the Morinda citrifolia plant which may be present in some compositions of the present invention. For example, some compositions comprise leaf extract and / or leaf juice as further described herein.

Some compositions comprise a leaf serum that is comprised of both leaf extract and fruit juice obtained from the Morinda citrifolia plant. Some compositions of the present invention comprise leaf serum and / or various leaf extracts as incorporated into a nutraceutical product ("nutraceutical" herein refers to any drug or product designed to improve the health of living organisms such as humans or other animals).

In some embodiments of the present invention, Morinda citrifolia leaf extracts are obtained using the following process. Firstly, relatively dry leaves from the Morinda citrifoliaL plant. they are collected, cut into small pieces, and placed in a shredding device - preferably a hydraulic press - where the sheet pieces are crushed. In some embodiments, the crushed sheet pieces are then impregnated with alcohol such as ethanol, methanol, ethyl acetate, or other alcohol based derivatives using methods known in the art. Next, in some embodiments, alcohol and all alcohol-soluble ingredients are extracted from the crushed leaf leaves, leaving a leaf extract which is then heat reduced to remove all liquid from the same. The resulting dry leaf extract will be referred to hereinafter as the "primary leaf extract".

In some embodiments of the present invention, the primary leaf extract is pasteurized to at least partially sterilize the extract and destroy questionable organisms. The primary leaf extract is preferably pasteurized at a temperature ranging from 70 to 80 degrees Celsius and for a sufficient period of time to destroy any questionable organisms without major chemical alteration of the extract. Pasteurization may also be performed according to various methods or techniques of radiation.

In some embodiments of the present invention, the pasteurized primary leaf extract is placed in a centrifuge decanter where it is centrifuged to remove or separate any leaf juice remaining therein from other materials, including chlorophyll. Upon completion of the decentrifuge cycle, the leaf extract is in a relatively purified stable. This purified leaf extract is then pasteurized in a similar manner as discussed above to obtain a purified primary leaf extract.

Preferably, the kerosene and / or purified primary leaf extract is further fractionated into two individual fractions: a dry hexane fraction, an aqueous methanol fraction. This is preferably accomplished by gas chromatography containing silicon dioxide and CH2-Cl2 MeOH ingredients using methods well known in the art. In some embodiments of the present invention, the methanol fraction is further fractionated to obtain secondary methanolols fractions. In some embodiments, the hexane fraction is further fractionated to obtain hexanesecondary fractions.

One or more of the leaf extracts, including the primary leaf extract, the hexane fraction, the methanol fraction, or any of the hexane or secondary methanols fractions may be combined with the fruit juice of the Morinda citrifolia fruity plant to obtain a whey. (the process of obtaining fruit juice to be described further herein). In some embodiments, the defoliation serum is packaged and frozen ready for transport; in others, it is additionally incorporated into a pharmaceutical product as explained herein.

3. Morinda citrifolia fruit processing

Some embodiments of the present invention include a composition comprising fruit juice of the Morindacitrifolia plant. Since Morinda citrifolia fruit is inedible for all practical purposes, the fruit must be processed to make it enjoyable for human consumption; and included in the compositions of the present invention. Processed Morinda citrifolia fruit juice can be prepared by separating seeds and peels from the juice and pulp of a ripe Morinda citrifolia fruit, filtering the pulp from the juice; and pack the juice.

Alternatively, instead of packing the juice, the juice can be immediately included as an ingredient in another frozen or pasteurized product. In some embodiments of the present invention, juice and pulp may be formed by pushing a homogeneous mixture to be mixed with other ingredients. Other processes include drying by freezing fruit and juice. Fruit and juice may be reconstituted during production of the final juice product. Still other processes may include air drying the fruit and juices before being crushed.

In a currently preferred process of producing Morinda citrifolia fruit juice, the fruit is picked by hand or handled with mechanical equipment. Fruit can be harvested when it is at least 2 - 3 cm and up to 24 - 3 6 cm in diameter. The fruit preferably has a color ranging from dark green to yellow-green to a white color, and intermediate color gradations. The fruit is totally clean after harvest and before any processing takes place.

The fruit is allowed to ripen or age from 0 to 14 days, but preferably for 2 to 3 days. The fruit is ripened or aged by being placed in equipment so that the fruit does not contact the soil. The fruit is preferably covered with a cloth or aging reductive material, but the fruit may be aged without being covered. When ready for further processing the fruit is light in color, such as light green, light yellow, white or translucent color. The fruit is inspected for damage or excessive green color and firmness. Hard and damaged green fruits are separated from acceptable fruits.

Ripened and aged fruit is preferably placed in plastic lining containers for further processing and transport. Aged fruit containers can be kept from 0 to 30 days, but preferably theft containers are kept for 7 to 14 days prior to processing. Containers may optionally be stored under refrigerated conditions prior to further processing. The fruit is unpacked from the storage containers and processed by a manual or mechanical separator. Assed and peel are separated from the juice and pulp.

The juice and pulp can be packed in storage and transport containers. Alternatively, the juice and pulp can be immediately processed into a finished juice product. Containers may be stored at room temperature, frozen or refrigerated. Morinda citrifolia pulp and juice are preferably mixed in a homogeneous mixture, after which they can be mixed with other ingredients such as flavorings, sweeteners, nutritional ingredients, botanicals and colorants. The finished juice product is preferably heated and pasteurized to a minimum temperature of 830 ° C or higher to 100 ° C. Another manufactured product is Morinda citrifolia puree and puree juice, in concentrated or diluted form. Mash is essentially the pulp separated from the seeds and is different from the fruit juice product described here.

The product is filled and sealed in a plastic, glass or other appropriate material end container that can withstand processing temperatures. Recipients are kept at filling temperature or can be cooled quickly and then placed in a transport container. The shipping containers are preferably wrapped with a material and in a manner to maintain or control the temperature of the product in the final containers.

The juice and pulp can be further processed by separating the pulp from the juice through a filtration equipment. The filtration equipment preferably consists of, but is not limited to, a centrifuge decanter, a screen filter with a size of 1 micron up to 2000 microns, more preferably smaller than 500 microns, a filter press, a reverse osmosis filtration device, and any other standard commercial filtration devices. The operating filter pressure preferably ranges from 0.1 MPa to about 7 MPa. The flow rate preferably ranges from 0.38 l.p.m. (liter per minute) to 3785.4 lpm, and more preferably between 18.9 and 189.3 lpm. The wet pulp is washed and filtered at least once and up to 10 times to remove any juice from the pulp. The resulting pulp extract typically has a fiber content of 10 to 40% by weight. The pulping result is preferably pasteurized to a temperature of at least 830 ° C and then packaged in drums for further processing or transformed into a high fiber product.

4. Morinda citrifolia seed processing

Some Morinda citrifolia compositions of the present invention include seeds from the Morindacitrifolia plant. In some embodiments of the present invention, Morinda citrifolia seeds are processed by spraying them into a seed powder in a laboratory mill. In some embodiments, the seed powder is left untreated. In some embodiments, the de-dusting powder is additionally fat free by dipping and stirring the hexane powder - preferably for 1 hour at room temperature (drug: hexane - ratio 1:10). The residue, in some embodiments, is then vacuum filtered without grease again (preferably for 30 minutes under the same conditions) and vacuum filtered again. The dust can be kept overnight in a fumehood to remove residual hexane.

Still further, in some embodiments of the present invention, the fat-free and / or untreated powder is extracted, preferably with 50% (w / w) ethanol for 24 hours at room temperature in a 1: 2 drug solvent ratio.

5. Morinda citrifolia Oil Processing

Some embodiments of the present invention may comprise oil extracted from the Morindacitrifolia plant. The method for extracting and processing the oil is described in United States Patent Application 09 / 384,785, filed August 27, 1999 and issued as Patent Number 6,214,351 on April 10, 2001, which is incorporated by reference herein. Morindacitrifolia oil typically includes a mixture of several different fatty acids such as triglycerides, such as palmitic, stearic, oleic and linoleic fatty acids, and other fatty acids present in smaller amounts. In addition, the oil preferably includes an antioxidant to inhibit oil damage. Conventional food-type antioxidants are preferably used.

6. General discussion of animal food products

Feed products have become more advanced in their ability to specifically target and meet the specific needs of different animals. Various feed preparations are disclosed in United States Patent Application 6,737,089 which is incorporated in its entirety.

The present invention contemplates administering various forms of M. citrifolia with additional nutrients. Non-limiting examples of products that may be administered to animals include: M. citrifolia plus glycosaminoglycans, M. citrifolia plus hyaluronic acid, M. citrifolia plus glucosamine HCl, M. citrifolia plus glucosamine sulfate, and M. citrifolia plus decondroitin sulfate. Other nonlimiting examples of formulations containing M. citrifolia which may be administered to animals include: M. citrifolia plus essential amino acids, Μ. citrifolia plus essential fatty acids, M. citrifoliamore long chain fatty acids, M. citrifolia plus omega 3 fatty acids, M. citrifolia plus omega 6 fatty acids, M. citrifolia plus macro minerals, M.citrifolia plus micro minerals, M. citrifolia more peptide chains, M. citrifolia plus amino acids of branched chain, M. citrifolia puree plus noniinteira seeds, M. citrifolia puree plus whole nonitorrada seeds, M. citrifolia puree plus whole roasted fat free denoni seeds, M. puree citrifoliamore non-fat roasted cracked noni seeds, purée M. citrifolia plus non-roasted cracked noni seeds, M. citrifolia puree plus ground-roasted noni seeds, M. citrifolia puree plus fat-roasted nonimoida seeds, puree M. citrifolia noni toasted flaked seeds, M.citrifolia puree plus noni toasted flaked seeds, M. citrifolia puree plus non-fat toasted flakes roasted noniextruded and mashed M. citrifolia plus roasted extruded noni seeds.

The present invention provides for the administration of various forms of M. citrifolia-reinforced products. Non-limiting examples of such forms include: pellet, extruded pieces, extruded flake, penetration pieces, liquid water system, semi-solid liquid salt deposit tank system, gel, low-moisture gel, and gel pellet. with low moisture content.

The method of distribution of reinforced products with M. Citrifolia can be very important. Non-limiting examples of delivery methods include surface-incubation ration with an M. citrifolia product, adding the same to feeding practices used for new calves including adding M.citrifolia product to colostrums given to new calves born after birth, soaking with products reinforced with M. citrifolia to improve mastitis in the dairy industry.

There are several considerations that may be included in determining which form of administration the M.citrifolia product should have. Some non-limiting examples of consideration include: pleasant taste - cows / animals will eat the product, suggested intake - what will be the proper dosage, milk flavor - will spoil the aroma of milk in the dairy industry, incorporation into the feed - can be conveniently added to the feed without significantly reducing its intake. Mixing efficiency, and uniformity - can be mixed into the feed in a uniform and compatible form so that we can be sure that each animal is receiving the proper dosage.

Applicants consider fully mixing M. citrifolia-reinforced products with animal feed. In a non-limiting example the applicants proposed to mix M.citrifolia-reinforced products with grains or hay. In another non-limiting example the applicants proposed to mix M. citrifolia with a water medication medium.

7. Compositions and their use

The present invention provides compositions and methods for administering various M.citrifolia-reinforced products to animals to improve various physiological conditions. For example, the products of the present invention may be used to reinforce moisture against gram negative infections. Embodiments of the present invention also comprise methods for internally and / or externally introducing a composition of Morindacitrifolia into the body of an animal. Various embodiments of the Morinda citrifolia compositions comprise several different ingredients, each embodiment comprising one or more forms of a Morinda citrifolia component processed as taught and explained herein.

Some embodiments of the invention include one or more processed Morinda citrifolia components such as: extract from Morinda citrifolia leaves, hot leaf extract, processed Morindacitrifolia leaf ethanol extract, steam distilled extract of processed Morinda citrifolia leaf, Morinda citrifolia fruit, Morinda citrifolia extract, Morinda citrifolia fibradietetic, Morindacitrifolia puree juice, Morinda citrifolia puree, Juice concentrate Morinda citrifolia puree, Morinda citrifolia puree juice concentrate, Frozen, concentrated Morinda fruit juice and evaporated concentration of Morinda citrifolia fruit juice, whole fresh fruit of Morinda citrifolia, whole dried fruit of Morindacitrifolia, solvent or powder extracted forms as well as enzyme-treated Morinda citrifolia seeds or any other processed Morinda citrifolia seed (ie toasting, blanching microwave tr heat treatment, immersion in water or water solutions of various salts or chemical compounds), whole Morinda citrifolia fruit with attached buds or flowers, leaf extracts, leafless juice, and untreated fat-free seed extracts. may include several other ingredients. Examples of other ingredients include, but are not limited to: artificial flavoring, other natural juices or juice concentrates such as a natural juice concentrate or a natural blueberry juice concentrate; vehicle ingredients; and others as will be further explained herein.

The present invention provides for the administration of various forms of M. citrifolia with and without additional nutrients. Non-limiting examples of products that may be administered to animals include: M. citrifolia plus glycosaminoglycans, M. citrifolia plus hyaluronic acid, M. citrifolia plus glucosamine HCl, M. citrifolia plus glucosamine sulfate, and M. citrifolia plus decondroitin sulfate. Other nonlimiting examples of formulations containing M. citrifolia which may be administered to animals include: M. citrifolia plus essential amino acids, M. citrifolia plus essential fatty acids, M. citrifoliamore long chain fatty acids, M. citrifolia plus omega 3 fatty acids, M. citrifolia plus omega 6 fatty acids, M. citrifolia plus macro minerals, M.citrifolia plus micro minerals, M. citrifolia more peptide chains, M. citrifolia plus amino acids of branched chain, M. citrifolia puree plus noniinteira seeds, M. citrifolia puree plus whole nonitorrada seeds, M. citrifolia puree plus whole roasted fat free denoni seeds, M. puree citrifoliamore non-fat roasted cracked noni seeds, mashed M. citrifolia plus non-roasted cracked noni seeds, M. citri folia puree plus ground-roasted noni seeds, M. citri folia puree plus non-fat roasted roasted seeds, mashed M. citrifolia plus non-fat flaked roasted noni seeds, M.citrifolia puree plus non-roasted flaked noni seeds, puree M. citrifolia plus non-fat seeds a toasted noniextruded, M. citrifolia puree plus extruded denoni seed extracts and noni.treated citrus citrus puree plus toasted extruded noni seed extracts.

Any compositions having the leaf extract from Morinda citrifolia leaves may comprise one or more of the following: the primary leaf extract, hexane fraction, the methanol fraction, the hexane and methanol fractions, the leaf serum or nutraceutical leaf.

In some embodiments of the present invention, active ingredients or compound compounds of Morindacitrifolia may be extracted using various procedures and processes commonly known in the art.

For example, the active ingredients may be isolated and extracted using alcohol or alcohol based solutions such as methanol, ethanol, and ethyl acetate, and other alcohol based derivatives using known art methods. These active ingredients or compounds may be isolated and further fractionated or separated from one another into their constituent parts. Preferably, the compounds are separated or fractionated to identify any active ingredients that could help prevent disease, increase health, or perform other similar functions. In addition, the compounds may be fractionated or separated into their constituent parts to identify and isolate any dependent or critical interactions that could provide the same health-enhancing functions just mentioned.

Any Morindacitrifolia components and compositions may be further incorporated into a nutraceutical product (again, "nutraceutical" herein referring to any product designed to improve the health of living organisms such as humans or other animals). Examples of nutraceutical products may include, but are not limited to: intravenous products, topical dermal products, wound healing products, burn treatment and healing products, first aid products, antibacterial products, bone healing and healing products, anti-inflammatory products, eye drops, antifungal products, arthritis treatment products, muscle relaxants, and various nutraceutical and other products as may be further discussed here.

The compositions of the present invention may be formulated in any of a variety of embodiments, including oral compositions, topical dermal solutions, intravenous solutions, and other products or compositions.

Oral compositions may take the form of, for example, tablets, cakes, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, syrups or elixirs. Compositions intended for oral use may be prepared according to any known method in the art, and such compositions may contain one or more agents such as sweetening agents, flavoring agents, coloring agents, and preserving agents. They may also contain one or more additional ingredients such as vitamins and minerals, etc. Tablets may be manufactured to contain one or more Morinda citrifolia components in admixture with non-toxic, pharmaceutically acceptable excipients which are suitable for tablet manufacture. Such excipients may be, for example, inert diluents, granulating and disintegrating agents, binding agents, and lubricating agents. The tablets may be uncoated or may be coated by known techniques to retard disintegration and absorption in the gastrointestinal tract and thereby provide continued action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be used.

Aqueous suspensions may be manufactured to contain Morinda citrifolia components in admixture with excipients suitable for the manufacture of aqueous suspensions. Examples of such excipients include, but are not limited to: suspending agents such as sodium carboxy methylcellulose, methyl cellulose, hydroxy propyl methylcellulose, sodium alginate, polyvinyl pyrrolidone, gumtragacanth and acacia gum; wetting or dispersing agents such as naturally occurring phosphatide comolecithin, or alkylene oxide condensation products with fatty acids such as polyoxyethylene stearate, or ethylene oxide condensation products with heptadecaethyleneoxyetethanol, or ethoxide ethoxide oxide condensation products derivatives of fatty acids and urahexitol such as polyoxyethylene sorbitan monooleate, or ethylene oxide condensation products with partial esters derived from fatty acids and dehexitol anhydrides such as polyethylene sorbitan monooleate.

Typical sweetening agents may include, but are not limited to: natural sugars derived from maize, beet, sugar cane, potato, tapioca or other source containing starch which may be chemically or enzymatically converted to crystalline pieces, powders and / or syrups. In addition, sweeteners may comprise artificial or high intensity sweeteners, some of which may include aspartame, sucralose, stevia, saccharin, etc. The concentration of sweeteners may be between 0 and 50% by weight of the composition of Morinda citrifolia, and most preferably between about 1 and 5% by weight.

Typical flavoring agents may include, but are not limited to, artificial / natural flavoring ingredients that contribute to the pleasant taste. Flavor concentration may vary, for example, from 0 to 15% by weight of the composition of Morinda citrifolia. Coloring agents may include food-grade or natural artificial coloring agents having a concentration of from 0 to 10% by weight of the composition of Morindacitri folia.

Typical nutritional ingredients may include: vitamins; minerals; residual elements; herbs; botanical extracts; bioactive chemicals and compounds from 0 to 10% by weight of the composition of Morinda citrifolia. Examples of vitamins include, but are not limited to, vitamins A, B1 through B12, C, D, E, folic acid, pantothenic acid, biotin, etc. Examples of minerals and residual elements include, but are not limited to, calcium, chromium, copper, cobalt, boron, magnesium, iron, selenium, manganese, molybdenum, potassium, iodine, zinc, phosphorus, etc. Herbs and botanical extracts may include, but are not limited to, alfalfa, bee pollen, chlorella powder, Dong Quai powder, Ecchinacea root, Gingko Biloba extract, Ponytail herb, Blackberry, Shitake mushroom, spirulina seaweed, dementing extract grape, etc. Typical bioactive chemicals may include, but are not limited to, caffeine, ephedrine, L-carnitine, creatine, lycopene, etc.

The ingredients to be used in a topical dermal may include whatever may be internalized in the body of a mammal and there may be various forms such as gels, lotions, creams, ointments, etc., each comprising one or more carrier agents. The ingredients or carrier agents incorporated in systemically administered compositions (e.g. intravenously) may also comprise any known in the art. In one exemplary embodiment, a Morinda citrifolia composition of the present invention comprises one or more of a processed Morindacitrifolia component present in an amount by weight of from about 0.01 to 100% by weight, preferably from 0.01 to 95% by weight. Various formulation modalities are included in patent number 6,214,351, issued April 10, 2001, which is incorporated in its entirety herein. However, such compositions are intended for exemplary use only, as one of ordinary skill in the art will recognize other formulations or compositions comprising the processed Morinda citrifolia product.

In another exemplary embodiment, the internal composition comprises the ingredients of: processed fruit juice or Morinda citrifolia depurate juice present in an amount by weight of from about 0.1 - 80%; processed Morinda citrifolia oil present in an amount by weight of from about 0.1 - 20%; and a vehicular medium present in an amount by weight of approximately 20 - 90%. Morinda citrifolia puree juice or fruit juice can also be formulated with a processed Morinda citrifolia dietary fiber product present in similar concentrations.

The juice and pulp can be dried using a variety of methods. The pulp and juice mixture may be sparged or enzymatically treated prior to drying. The enzymatic process begins by heating the product to a temperature between 32.9 ° C and 57.2 ° C. It is then treated with a single enzyme or a combination of enzymes. These enzymes include, but are not limited to, amylase, lipase, protease, cellulase, bromelain, etc. The juice and pulp may also be dried with other ingredients, such as those described above with respect to the high fiber product. The typical nutritional profile of dried juice and pulp is 1 to 20% moisture, 0.1 to 15% protein, 0.1 to 20% fiber, and mineral and vitamin content.

The filtered juice and water from washing the pulp is preferably mixed together. The sucofiltrate is preferably evaporated under vacuum to a brix of 40 to 70 and a humidity of 0.1 to 80%, more preferably 25 to 75%. The resulting concentrated Morinda citrifolia juice may or may not be pasteurized. The juice would be pasteurized in circumstances where the sugar content or water activity was low enough to prevent microbial growth. It is packaged for storage, transportation and / or further processing.

Pet food products have become more advanced in their ability to specifically target and address the specific needs of different animals. Various pet food preparations are disclosed in United States Patent Application 6,737,089 which is incorporated herein in its entirety.

8. Distribution Systems and Forms

The present invention contemplates administering various forms of M. citrifolia-reinforced products. Non-limiting examples of such forms include: pellet, extruded pieces, extruded flake, penetration pieces, liquid water system, semi-solid liquid salty tank system, gel, low moisture gel, and low content gel pellet of moisture.

Distribution Methods

Some non-limiting examples of distribution methods include surface fertilization of the feed with a M. citrifolia product, adding the same in formaliquid to the dry feed normally supplied to that species or drying the M. citrifolia product and adding the same ground, granular or pellet form. Liquid M.citrifolia products are simply mixed in the proper ratio with another liquid feed. Penetrating pellets are used for fish or other water-dwelling creatures. The M. citrifolia additives are liquid or dry, are mixed in the feed in a uniform and consistent manner so that it can be ensured that each animal is receiving the appropriate amount for uniform benefits.

One method for administering M. citrifolia-fortified feed products is by administering a liquid or large dose of "purging" ("purging") throwing about one quarter or one liter of product to each cow, horse, ram and / or other animal. once from M. citrifolia-reinforced products.

Forms of administration

The present invention contemplates administering various forms of M. citrifolia-reinforced products. Non-limiting examples of such forms include: pellet, chunks, extruded, extruded flake, penetration chunks, liquid water system, semi-solid liquid salty tank system, gel, low moisture gel, low gel pellet moisture content.

The method of distribution of reinforced products with M. Citrifolia can be very important. Non-limiting examples of distribution methods include surface fertilization of the feed with an M. citrifolia product, adding the same to the feeding practices used for new calves including adding the M.citrifolia product to colostrums given to newborn calves shortly after birth, immersion in produtos-reinforced products. citrifolia to improve mastitis in the dairy industry.

There are several considerations that may be included in determining which form of administration the M.citrifolia product should have. Some non-limiting examples of consideration include: pleasant taste - cows / animals will eat the product, dosage - what will be the proper dosage, milk flavor - will spoil the milk taste in the dairy industry, incorporation into the feed - can be conveniently added to the feed without significantly reducing its Mixing efficiency and uniformity can be mixed into the feed in a uniform and consistent manner so that it is assured that each animal is receiving the proper dosage.

Applicants consider mixing the reinforced products with M. citrifolia with the feed consumed by the animals. In a non-limiting example the applicants proposed mixing M.citrifolia-reinforced products with grains or hay. In another non-limiting example they proposed mixing M. citrifolia with a water medication.

The effect of M. citrifolia-reinforced products of M. citrifolia puree, for example, on mastitis is of interest. Using a "purgative" with an M. citrifolia-strengthened product where a distressed animal is administered a large dose, a non-limiting example of a large dose may include more than two ounces, one quarter, two quarters, three quarters, more than three quarters in a periodic basis, wherein a nonlimiting example of a periodic basis may include once every other day, once a day, twice a day, or more than twice a day. Since the somatic cell count (SCC) of each cow is done periodically, it can be seen immediately whether or not the products reinforced with M. citri folia had the desired effect. In another non-limiting example herds or whole animal groups may be treated, as described above, to improve or avoid undesirable physiological conditions or to increase or improve desirable physiological conditions.

Decreased antibiotic use can be achieved by administering several M.citrifolia-reinforced products instead.

Several experiments have been conducted that indicate that the taste and smell of M. citrifolia reinforced products do not affect the taste or smell of milk from cattle and received M. citrifolia reinforced products, and that the reinforced products are tasty to animals.

In addition, experiments have shown that successfully treating mastitis by infusion of the infected room with M. citrifolia-reinforced products and friction of M. citrifolia-reinforced products in the udder to relieve pain and inflammation. Further experiments have shown that the administration of newborn citrus-enhanced M. citrifolia-reinforced products prevents calves from having bovine dissent. In a non-limiting example, newborn calves received 56.7 g twice daily, substantially reduced the mortality rate of newborn calves, and substantially improved weight gain.

9. Examples The following examples are given to illustrate various embodiments that have been or may be made according to the present invention and are given by way of example only. It should be understood that the following examples are not all inclusive, comprehensive, or exhaustive of the many types of embodiments of the present invention. present invention which may be prepared according to technology as described herein.

Example 1: Calf Experiments In a 100 calf experiment, those who received two ounces of Tahitian Noni puree twice a day outnumbered those who received no treatment by 0.4 kg a day from birth to weaning. 8% faster than calves not in treatment. This resulted in a weight advantage of 2.87 kg at weaning. The mean age at weaning was 66 days, the average weight at weaning 70.3 kg. These results were subjected to a rigorous statistical analysis which found that they are significant at 99.9967% for average daily gain and 99.9996% for ganhototal. A rating of 95% is generally considered to be significant. Male calves gained at a slightly faster rate than females, but these differences were not statistically significant. Fifty male calves and fifty female calves were randomly assigned to treatment or nontreatment groups at birth. All calves were weighed at birth and weaned again to obtain the reported results. The calves were fed by bucket with pasteurized whole milk. A custom starter concentrate was offered, free choice, from day one.

Example 2: Experiments with Pigs

Noni puree in a gel form was given sucklings in three different experiments. In the first experiment 10 litter piglets were identified and divided into four groups in such a way as to minimize differences due to litter and sex. All these piglets were from genetically similar sows and all artificially bred by the same boar to minimize genetic differences.

Two days before weaning, the piglets from both groups were force-fed noni puree gel by inserting a tube into their mouths and providing 5 cm3 dogel. Two control groups received no treatment. Each group of piglets was weighed at the beginning of the experiment and weekly thereafter for three weeks. Here are the results.

First experiment

<table> table see original document page 34 </column> </row> <table>

Treated pigs gained a total of 134.7 kg compared to 91.6 kg for controls, a 47% advantage for treated pigs. This is especially noteworthy because there is concern that treating pigs daily would have a negative effect on their cattle rate. Treated pigs were cared for individually on a daily basis while untreated pigs were simply weighed on a weekly basis. If these results could be routinely obtained it would mean an advantage of 1.35 kg per pig.

In the second experiment, 10 pig litters from genetically similar sows reared by the same pig were divided into two groups of five litters. Litters on the east side of the sty served as a group and the west side of the sty as the second group. Starting at one week old, the pigs in a group were force-fed noni mash for 10 days while the other group received no treatment. Each group was weighed daily. Here are the results.

Second experiment

<table> table see original document page 35 </column> </row> <table>

There were 98 pigs in this experiment at the beginning with death from one in the untreated group on the second day. Although pigs in the treated group gained more than those in the untreated group, the results are inconclusive.

At weaning time, the 22 treated and untreated upper four hogs in the group, with consideration given to nesting and sex, were placed in two pens for the third experiment. Pigs in the treatment group continued to force feed 5 cm3 of purenon gel per day and pigs in the untreated group continued without treatment. Each group was weighed at baseline and weekly thereafter. Here are the results.

Third experiment

<table> table see original document page 36 </column> </row> <table>

Treated pigs gained 13.5% more than untreated pigs, an advantage not as large as in experiment number 1 but still totaling 0.39 kg per pig. The owner noted that the treated pigs were extremely fearful at the end of the term and had been caring for 31 days daily, emphasizing once again that a more efficient means of administering the product needed to be developed. Force feeding by tube is very labor intensive and disadvantageous to pigs as a stressor.

Example 3: Dairy Calf Stress Test Three hundred and seventy-two dairy calves were entered into a stress experiment. These one-day calves have been purchased from numerous pastureland farms. Eighty-four calves (58 males and 26 females) received on the farm on the first day of the experiment were force-fed with 15 cm3 of noni puree collection time by inserting a tube into their mouths and squeezing the gel into the back of their tongues. . Another 15 cm3 were given to each calf after unloading on the farm. Each of these 84 calves was subsequently treated again, morning and evening, for the next six days.

A second group of 135 calves (101 males and 34 females) received on making on the second day of the experiment were fed 15 cm3 of noni puree gel at take-off and an additional 15 cm3 at discharge. These 135 calves were subsequently treated in the morning and evening for an additional two days.

A third group of 153 calves (116 males and 37 females) received on the farm on day 9 of the experiment received no treatment.

All calves, whether or not receiving noni puree, also received a 2 cm3 injection of antibacterial vaccine upon arrival at the farm.

Calves were examined daily for signs of disease. One observation was made every day of calf leftover showing clinical signs of dysenteriabovine. Medicines administered by farm staff were also recorded for each calf. Some calves considered too small were sold. These sales were recorded as well as all deaths. Here is a summary of the logged information. ALL VEHICLES

<table> table see original document page 38 </column> </row> <table>

Numbers in parentheses are percentage based on number of calves, truncated decimals in three places.

MALE VITELES ONLY <table> table see original document page 38 </column> </row> <table> <table> table see original document page 39 </column> </row> <table>

ONLY FEMALE VEHICLES

<table> table see original document page 39 </column> </row> <table> <table> table see original document page 40 </column> </row> <table>

Problems with bovine dysentery were minimal in early harvested vitruses (in the first two days), increased sharply in those caught during the next four days and then sharply tapered during the last six days.

The rapid, short-term purine treatment of nonine levels used in this experiment did nothing to reduce stress in the treated animals. In fact, treatment for three days seemed to increase stress. In fact, this makes sense because the treatment itself was stressful. When added on top of the stress of being changed it proved to be a formidable obstacle to the calves involved.

Seven-day treatment proved to be very advantageous compared to three-day treatment, especially considering the high correlation between health problems and time of collection. There was some visual evidence that calves treated for seven days performed better overall than any others. There were no easily apparent differences in response due to sex.

Example 4: In vitro Rumine Fluid Experiment

The experiments were conducted to determine whether M. citrifolia-reinforced products would have any adverse effect on ruminants. The results indicated that not only will they not be detrimental to ruminal fermentation, but may have some significant benefits.

Although no major effect on invitro ruminal fermentation was detected with the addition of Morindacitrifolia extract, some promising results were observed.

Although the disappearance of dry matter and VFA total concentrations were not affected in this study, the inclusion of the extract, particularly at the lowest inclusion level (1% of substrate), had significant effects on the final fermentation products. This is important because it suggests differences in energy efficiency of fermentation and potential differences in the use of dietary protein by ruminal microorganisms. Ruminal pyropionate production is associated with lower hydrogen production than acetate or butyrate production.

Typically, when propionate production is increased, less methane is produced, resulting in more energy efficient use. In addition, propionate may stimulate production in ruminants serving as a glycogen substrate. The decrease in ratified chain VFA ratios suggests a decrease in rumen proteolysis and / or desamination. In most diets, the protection of dietary protein from ruminal degradation is expected to result in increased protein utilization efficiency.

Example 5: Pleasant Taste

Applicants administered M. citrifolia puree to a group of four pigs. They administered a formulation that contained no additional flavoring and four additional formulations with varying levels of mint added. The pigs have been observed for over an hour but never indicated any inclination to try any of the product versions. They smelled a little, but did not try to eat. Pigs do not like the product and do not eat on their own. Applicants have proposed that the solution to this problem is to administer the M.citrifolia product as approximately one% of the daily feed of these pigs. A% would do very little if any difference in flavor of the total feed mix.

In addition, applicants plan to use sugar instead of mint to flavor the M.citrifolia product. Additionally, they plan to mix the M product. citrifolia with one vehicle and then place the vehicle through the mixing process with the rest of the feed. For example, if it is necessary to add one gallon of prodononi (liquid) to 453.6 kg of feed, they could mix a gallon in 4.5 kg of a suitable vehicle and then the 5.3 kg of vehicle could be mixed in 453.6 kg. kg ration.

The applicants have found that it is easy to mix the feed puree and the piglets are not prone to eating. Additionally, they mixed the M. citrifolia milk substitute products for some piglets and found that the milk substitute piglets had no difficulty in eating the M.cififolia-reinforced products under these circumstances. Additionally, they observed that sows will consume M. citrifolias product in vehicle.

Example 6: Experiments with poultry The research performed as discussed below indicated that diets reinforced with M. citrifolia ("Noni") did not cause harm and there was a difference of approximately 3.6% in weight gain between the treatment group and the control group. .

The efficacy of Noni as a supplement for animals under intensive production systems has not been explored before. A recent limited experiment was conducted with weaned pigs that were purged with 5 ml of liquid Noni, supplemented twice daily from a live weight of 5-23 kg. Treatment markedly increased pig performance and induced interest in Noni with a possible supplement to poultry.

Chickens have been selected due to their early rapid growth. 40-41 g broiler chickens on average day-old and increase by 3.8, 2.6, 1.8 and 1.6 times the weight of previous weeks at 1, 2, 3 and 4 weeks old . Consequently, a two-week experiment represents a period of intense growth and adaptation to the environment. Under praxis conditions a dietary supplement that mitigates the effects of stressors and / or more ability to live, growth and / or feeding efficiency has tremendous market potential. The purpose of the study was to evaluate the Noni test material provided by MOR INDA, Inc. ® in departed chicken diets.

Materials & Methods

One-day-old chicks were tethered nasasas, weighed and distributed in 24 fenced-off enclosures in 8 blocks based on initial body weight. The brooder units were maintained in an environmentally controlled space with 60 m3 airflow, 18 hourly air exchange and 24 hour photoperiod. The little chicks were observed twice a day and water containers cleaned and refilled daily. Feed and water were provided ad libitum.

The chicks were fed a standard starter diet (control) and noni liquid supplement added by 1 and 2% in the basal diet. The starter diet contained 58.25% yellow corn, 3.5% soybean meal, 3.4% household fat, 1.4% dicalcium phosphate, 1.1% calcium carbonate, 0.25% of common salt, 0.25% vitamin premix, 0.15% decoline chloride premix, 0.15% DL-methionine, and 0.05% residual mineral mixture. Due to the lack of information on Noni supplement stability, 150 kg of the control diet were prepared and weekly noni puree experimental diets were prepared. Feed intake, body weight, and ability to live were measured at 2 weeks of age. Fangs grow in litter and fecal moisture is important for litter condition, poultry health, and poultry meat quality and therefore dry matter defecations. measured on days 13-14.

The experiment consisted of three treatments (0, 1 and 2% Noni puree) that were randomly assigned to a complete randomized block design with 8 blocks. An enclosure of 8-9 birds was the experimental unit. Body weights, 1 (one) day old and 14 (fourteen) days old, were recorded on an individual basis. The data were subjected to variance analysis using α = 0.05, and orthogonal polynomial contrasts were used to examine response to the test material dose (0, I and 2%). In the case of body weight data, individual values were used to move bird to bird variation in each experimental unit and treatment effect tested with the appropriate term deer. Standard and medium errors are displayed in the results section.

Results

Table 1. Performance of Noni feed supplemented chicken from 1 day to 14 days

<table> table see original document page 45 </column> </row> <table>

1 Noni animal feed supplement provided by Morinda®2 linear contrast (P = 0.19)

Statistically significant treatment differences (P <0.05) in the measured response variables were not detected. There were no abnormalities observed with the test material fed on 1 or 2% dadieta and the use of Noni feed supplement did not increase the fecal moisture content. Although a statistically significant treatment effect was not detected for body weight, there was a trend of improvement of 3.6% in body weight in 2% Noni diet supplement. The results clearly demonstrated that Noni supplementation had no adverse effects in terms of behavior, bird condition, moisture excretion, growth and feed efficiency.

Therefore the applicant's research indicates that:

1) noni diet supplement had no adverse effect included in up to 2% in the diet; and 2) a trend toward better body weight (3.6% gain) was evident in mothers fed the 2% Noni diet supplement.

These examples and their ingredients, illustrative of advances known in the prior art for feed products, can be significantly improved by the inclusion of Morinda citrifolia. as an ingredient. In so doing, these products may also provide additional advantages and benefits to the animals for which they are intended. As there are many different types of animal feed products, each containing significantly different ingredient compositions, the present invention seeks to provide a feed product that is capable of enhancing any specific composition or formulation by the addition of Morinda citrifolia dietary fiber. As a whole, several Examples have been provided which are discussed below where dietary fiber of Morindacitrifolia has been added to a specific composition of ingredients to create an improved and beneficial feed product.

Example 7: Mastitis / dairy cows experiments proposed

The present invention considers various experiments. A non-limiting example of a proposed experiment included administering M. citrifolia-reinforced products to animals to prevent or ameliorate mastitis. In one proposed experiment there is a pastoral farm that draws milk from approximately 1,000 cows two to three times a day. At any given moment they have approximately 12 heads with clinical mastitis.

In this pastoral farm clinic mastitis is detected by the name of milk. Wipers squeeze a little milk from each quarter of each cow out of the system before putting on the milk machine. Clinical mastitis will be immediately shown in this check. If present the milk is drawn into a separate container and not allowed to enter the volume tank with all other milk.

This farm is not about infected comantibiotic cows. Instead they make sure to dry-teat the cows each time and test the milk each time.

This pastoral farm has a machine in the barn that can take the SCC from each milk draw for each vaccinated. When the SCC goes down to the normal range, milk can again be removed from the cow in the normal volume system.

Such a proposed experiment would include administering a large dose or "purging" ("purging" means throwing each cow's nagoela approximately one quarter or one liter of product at a time, from M.citrifolia-reinforced products to half of infected cows on a daily basis with monitoring. subsequent SCC for each treated cow compared to those untreated infected cows.In addition, this experiment proposes to randomly divide the infected group into two groups.As mastitis disappears into one cow and that cow returns to the list of healthy cows, new to each other. of the healthy list would be randomized and half would be treated with M.citrifolia-reinforced product.The proposed experiment considers "purging" untreated animals with M.citrifolia-reinforced product using pure water only.

Example 8: Inhibition of COX-2, TNF-α, IL-1β, IL-8 & IL-6

The present invention provides compositions and methods for inhibiting COX-2, TNF-α, IL-β, IL-8 & IL-6. Modalities of the present invention also comprise methods for internally introducing a composition of Morindacitrifolia into the body of a mammal. Various embodiments of the Morinda citrifolia compositions comprise several different ingredients, each embodiment comprising one or more forms of a Morinda citrifolia component processed as taught and explained herein.

Administration of Morinda citrifolia products may modulate endotoxin-induced inflammatory responses (lipopolysaccharide, LPS) in equine pup monocytes by regular expression of cyclooxygenase-2 (COX-2), as well as expression of other inflammatory cytokines, specifically TNF-α, IL-β, and IL-6. A nonlimiting example of a Morinda citrifolia product that can be administered is TAHITIAN NONI® EQUINE ESSENTIALS ™.

In an exemplary study neonatal foals were enrolled in the study after adequate passive transfer (IgG> 800 mg / dl), be confirmed by a 24 hour SNAP IgG test. Subsequently, experimental foals (n = 2) received 60 ml of TAHITIAN NONI® EQUINE ESSENTIALS ™ orally twice daily for 60 days. The 2 remaining foals served as age-matched controls. On days 10 and 60, blood was taken from which the peripheral monocytes were isolated. Monocytes from each foal were divided into an untreated control group and a group that was stimulated with LPS for 2 hours at 1000 mg / ml. Quantitative PCR analysis of COX-2, TNF-a, IL-β, IL-8 & IL-6 mRNA expression was determined, expressed as relative mean (χ), alteration, and values obtained from control and control foals. experimental, bought.

On day 10, foals treated with TAHITIAN NONI® EQUINEESSENTIALS ™ had a dramatic one-time reduction in COX-2, TNF-α, IL-β, IL-8 & IL-6 expression in 23x LPS-stimulated monocytes, IOx, 15x, 30x and 35x, respectively, when compared with married pority controls.

Although less dramatic than results on day 10, a similar pattern was observed on day 60. Foals treated with TAHITIAN NONI® EQUINE ESSENTIALS ™ had reduced expression of COX-2, TNF-α, IL-β, IL-8 & IL-6 were 9x, 180x, 8.5x, 22x and 35x LPS stimulated cells. when compared to married controls by day.

Monocytes isolated from foals receiving TAHITIAN NONI® EQUINE ESSENTIALS ™ had markedly decreased COX-2, TNF-α, IL-β, IL-8 & IL-6 demRNA expression after LPS stimulation when compared to control controls. The reduction in expression of these pro-inflammatory mediators, most notably at 10 days of age, suggests that TAHITIAN NONI® EQUINE ESSENTIALS ™ may be a promising new anti-inflammatory therapy, warranting additional consideration of their clinical use.

The present invention may be incorporated into other specific forms without departing from its inventive concept or essential features. The modalities described should be considered in all respects only as illustrative and not restrictive. The scope of the invention is therefore indicated by the appended claims instead of the above description. All changes that are understood in the meaning and equivalence range of the claims should be covered within their scope.

Claims (19)

1. Dry bran food product, characterized in that it comprises: between 0.01% and 30% pasteurized fruit puree of M.citrifolia, between 70% and 99% dry food product, quercetin present in an amount between 0.01% and -10% by weight rutin present in an amount between 0.01% and 10% by weight; Amount of additives from the list consisting of M. citrifolia plus essential amino acids, M. citrifolia plus essential fatty acids, M. citrifolia plus long chain fatty acids, M. citrifolia plus omega 3 fatty acids, M. citrifolia plus omega fatty acids 6, M. citrifolia plus macro minerals, M. citrifolia plus micro minerals, M. citrifolia plus peptide chains, M. citrifolia plus branched chain amino acids, M. citrifolia puree plus non-seed, M. citrifolia puree plus non-torrent seeds whole, M. citrifolia puree plus roasted fat-free denoni seeds whole, M. citrifolia puree roasted fat-free cracked noni seeds, M. citrifolia puree plus roasted cracked noni seeds, M. citrifolia puree plus ground-roasted noni seeds, M. citrifolia puree plus non-fat roasted nonimo seeds, puree M. citrifolia plus non-fat roasted non-seed seeds, pureed of M.citrifolia plus roasted noni flaked seeds, purée M. citrifolia plus non-fat roasted noniextruded seeds and M. citrifolia puree plus roasted extruded noni seeds. Product according to Claim 1, characterized in that it further comprises a selected ingredient from a list consisting of: Morinda citrifolia leaf extract, hot leaf water extract, processed Morinda citrifolia leaf ethanol extract , processed Morinda citrifolia leaf distillation extract, Morinda citrifolia fruit juice, Morinda citrifolia extract, Morinda citrifolia dietary fiber, Morinda citrifolia puree juice, Morinda citrifolia puree concentrate, Morinda citrifolia fruit juice concentrate, Morinda citrifolia puree juice, concentrated, frozen Morindacitrifolia fruit juice and evaporated concentration Morinda citrifolia fruit juice, fresh Morinda citrifolia fruit, whole dried fruit of Morinda citrifolia, solvent-extracted forms of Morinda citrifolia seeds, treated Morindacitrifolia seeds with enzymes, Morindacitrifolia seed processes da, whole Morinda citrifolia fruit, leaf extracts, leaf juice, fatless Morinda citrifolia seed extract and untreated Morinda citrifolia seed extracts. Product according to claim 1, characterized in that it further comprises a selected ingredient from a list comprising: glycosaminoglycans, hyaluronic acid, glucosamine HCl, glucosamine sulfate, chondroitin sulfate, essential amino acids, essential fatty acids, decadeia fatty acids long, omega 3 fatty acids, omega 6 fatty acids, macro minerals, micro minerals plus, peptide chains, branched chain amino acids, whole noni seeds, whole roasted noni seeds, whole fat noni roasted seeds, roasted fat noni cracked seeds, seeds toasted cracked noni seeds, toasted nonimoida seeds, toasted noni ground minced seeds, toasted noni fat non-roasted seeds, toasted noniem non-fat roasted seeds, toasted noni extruded non-fat seeds. Product according to claim 1, characterized in that it further comprises a reactive ingredient selected from a group comprising scopoletin, octoanoic acid, potassium, vitamin C1 terpenoids, alkaloids, anthraquinones, nordamnacantal, morindone, rubiandin, B-sitosterol, carotene, vitamin A, flavone glycosides, linoleic acid, Alizarin, amino acids, acubin, L-asperuloside, caproic acid, caprylic acid, ursolic acid and putative proxeronins. 5. A feed product, in liquid form, characterized in that it comprises: between 0,01% and 30% pasteurized fruit puree of M.citrifolia, between 20% and 90% liquid feed quercetin present in an amount between 0.01% and -10% by weight rutin present in an amount between 0.01% and 10% by weight; Amount of additives from the list consisting of M. citrifolia plus essential amino acids, M. citrifolia plus essential fatty acids, M. citrifolia plus long chain fatty acids, M. citrifolia plus omega 3 fatty acids, M. citrifolia plus acid Omega 6 fatty acids, M. citrifolia plus macro minerals, M.citrifolia plus micro minerals, M. citrifolia plus peptide chains, M. citrifolia plus branched chain amino acids, M. citrifolia puree plus noniinteiras seeds, M. citrifolia puree plus seeds non-roasted seeds, M. citrifolia puree plus whole roasted non-fat denoni seeds, M. citrifolia puree plus fat-roasted roasted noni seeds, puree M. citrifolia plus roasted cracked noni seeds, M. citrifolia puree plus noni seeds freshly ground, M. citrifolia puree plus non-fat roasted nonimo seeds, M. citrifolia puree non-fat roasted non-seed seeds M.citrifolia more of noni seed flakes on toast, more purêde M. citrifolia seeds without fat noniextrusadas toast and M. citrifolia puree more sementesde noni extruded toast. Product according to Claim 5, characterized in that it further comprises a selected ingredient from a list consisting of: Morinda citrifolia leaf extract, hot leaf water extract, processed Morinda citrifolia leaf ethanol extract , processed Morinda citrifolia leaf distillation extract, Morinda citrifolia fruit juice, Morinda citrifolia extract, Morinda citrifolia dietary fiber, Morinda citrifolia puree juice, Morinda citrifolia puree concentrate, Morinda citrifolia fruit juice concentrate, Morinda citrifolia puree juice, concentrated, frozen Morindacitrifolia fruit juice and evaporated concentration Morinda citrifolia fruit juice, fresh Morinda citrifolia fruit, whole dried fruit of Morinda citrifolia, solvent-extracted forms of Morinda citrifolia seeds, treated Morindacitrifolia seeds with enzymes, Morindacitrifolia seed processes da, whole Morinda citrifolia fruit, leaf extracts, leaf juice, fatless Morinda citrifolia seed extract and untreated Morinda citrifolia seed extracts. Product according to claim 5, characterized in that it further comprises a selected ingredient from a list comprising: glycosaminoglycans, hyaluronic acid, glucosamine HCl, glucosamine sulfate, chondroitin sulfate, essential amino acids, essential fatty acids, decadeia fatty acids long, omega 3 fatty acids, omega 6 fatty acids, macro minerals, plus micro minerals, peptide chains, branched chain amino acids, whole noni seeds, whole roasted noni seeds, whole fat noni roasted seeds, roasted fat noni cracked seeds, seeds cracked noni roasted seeds, roasted nonimaged seeds, roasted noni fat ground seeds, roasted noni fat flaked seeds, roasted noniem flaked seeds, extruded noni fat roasted seeds, and roasted noni extruded seeds. Product according to claim 5, characterized in that it further comprises a reactive ingredient selected from a group comprising scopoletin, octoanoic acid, potassium, vitamin C, terpenoids, alkaloids, anthraquinones, nordamnacantal, morindone, rubiandin, B-sitosterol , carotene, vitamin A, flavone glycosides, linoleic acid, Alizarin, amino acids, acubin, L-asperuloside, caproic acid, caprylic acid, ursolic acid and putative proxeronins. 9. Morindacitrifolia-based dry food product comprising Morinda citrifolia puree fruit mixed with dry animal para-food and additives having a form from the list consisting of pellets, extruded pieces, extruded flakes, penetration pieces, distribution liquid form through a water system or salt deposit tank system, gelatinous and semi-solid forms, low moisture gels, low moisture gel pellets, bran, paste, loose feed, and sweet feed. Product according to Claim 9, characterized in that it further comprises a quantity of additives from the list consisting of M. citrifolia plus essential amino acids, M. citrifolia plus essential fatty acids, M. citrifolia plus decadeia longa fatty acids, M citrifolia plus omega 3 fatty acids, M. citrifolia plus Omega 6 fatty acids, M. citrifoliamore macro minerals, M. citrifolia plus micro minerals, M.citrifolia plus peptide chains, M. citrifolia plus branched chain amino acids, M. citrifoliamais whole noni seeds puree, M. puree citr citrifolia plus whole roasted noni seeds, mashed M. citrifoliamore whole roasted non fat seeds, pureed Μ. citrifoliã plus fat roasted noni seeds roasted, M. puree M. citrifoliã plus roasted noniracha seeds, M. citrifoliã more roasted denoni ground seeds, M. citrifoliã puree plus fat non roasted roasted seeds, M. citrifoliã pureemore seeds noni fat toasted flakes, M. citrifoli puree plus roasted noni seeds toasted flakes, M. citrifoliã puree plus roasted noniextruded nonfat seeds and M. citrifoliã puree plus toasted extruded noni seeds. Product according to Claim 9, characterized in that it further comprises a selected ingredient from a list consisting of: Morinda citrifolia leaf extract, hot leaf water extract, processed Morinda citrifolia leaf extract , processed Morinda citrifoliã avapor distillate extract, Morinda citrifoliã fruit juice, Morinda citrifoliã extract, Morinda citrifoliã dietary fiber, Morinda citrifoliã puree juice, Morinda citrifoliã puree concentrate, Morinda citrifoliã fruit juice concentrate Morinda citrifoliã puree juice, concentrated, frozen Morindacitrifoliã fruit juice and evaporated concentration Morinda citrifoliã fruit juice, fresh Morinda citrifoliã fruit, whole dried fruit of Morinda citrifoliã, solvent-extracted forms of Morinda citrifoliã seeds, treated Morindacitrifoliã seeds with enzymes, Morindaci seed processed trifoliã, whole citrifolia Morinda fruit, leaf extracts, leaf juice, fat free Morinda citrifolia seed extract and untreated Morinda citrifolia seed extracts. Product according to claim 9, characterized in that it further comprises a selected ingredient from a list comprising: glycosaminoglycans, hyaluronic acid, glucosamine HCl, glucosamine sulfate, chondroitin sulfate, essential amino acids, essential fatty acids, decadeia fatty acids long, omega 3 fatty acids, omega 6 fatty acids, macro minerals, micro minerals plus, peptide chains, branched chain amino acids, whole noni seeds, whole roasted noni seeds, whole fat noni roasted seeds, roasted fat noni cracked seeds, seeds cracked noni roasted seeds, roasted nonimaged seeds, roasted noni fat ground seeds, roasted noni fat flaked seeds, roasted noniem flaked seeds, extruded noni fat roasted seeds, and roasted noni extruded seeds. Product according to claim 9, characterized in that it further comprises an active ingredient selected from a group comprising quercetin, rutin, scopoletin, octoanoic acid, potassium, vitamin C, terpenoids, alkaloids, anthraquinones, nordamnacantal, morindone, rubiandin, B-sitosterol, carotene, vitamin A, flavone glycosides, linoleic acid, Alizarin, amino acids, acubin, L-asperuloside, caproic acid, caprylic acid, ursolic acid and putative proxeronins. 14. Animal feed method comprising the steps of: adding a processed Morinda citrifolia product to an alcohol-based solution, isolating and extracting an active ingredient from the processed Morinda citrifolia product from the solution, mixing the extracted active ingredient with other feed ingredients; and administer the feed to the animal. Method according to claim 14, characterized in that the processed Morindacitrifolia product comprises processed Morindacitrifolia fruit juice. Method according to Claim 14, characterized in that the processed Morindacitrifolia product comprises processed Morinda citrifolia puree. Method according to claim 14, characterized in that the alcohol-based solution is selected from the group consisting essentially of methanol, ethanol and ethyl acetate and other alcohol-based derivatives. Method according to claim 14, characterized in that the active ingredient is Quercetin. A method according to claim 18, characterized in that the active ingredient is Rutina which works synergistically with Quercetin.